Articles related to RESEARCH & CLINICAL TRIALS

Recent studies suggest that ALS may begin to develop shortly after conception, taking years or decades before symptoms appear, highlighting the importance of early intervention and lifestyle modifications.

Osimertinib significantly improved progression-free survival in patients with unresectable stage III EGFR-mutant NSCLC after chemoradiotherapy, with a hazard ratio of 0.16 compared to placebo.

Actigraphy devices revealed significant improvements in sleep patterns with nighttime levodopa use, despite patients not perceiving these changes subjectively.

Recent studies have identified a range of chemical compounds released by face masks, including microplastics, volatile organic compounds, and plasticizers, prompting a closer examination of potential cumulative exposure risks.

A recent study involving 20,440 older adults with kidney failure found that initiating dialysis at an eGFR below 12 mL/min/1.73 m2 resulted in a mean survival of 770 days over a 3-year period, compared to 761 days for those continuing medical management

The combination of ponatinib and blinatumomab demonstrated a 95% complete response rate and 91% 3-year overall survival rate in patients with Ph-positive ALL.